The Rotunda Hospital Receives Prestigious Award from the United States Department of Health and Human Services Centres for Disease Control and Prevention
• Only institution outside of the US to be recognised
• Hospital awarded for innovation in blood clot prevention
4th April 2016: The Rotunda Hospital has been awarded an ‘Honourable Mention’ by the U.S. Centres for Disease Control and Prevention (CDC)Healthcare-Associated Venous Thromboembolism (HA-VTE) Prevention Challenge, for its electronic tool, Thrombocalc, which helps to identify women who are at risk of pregnancy associated blood clots.
It is the only Hospital or medical facility outside of the United States to have been recognised by the CDC. Fellow winners include some of the largest health systems in the USA including the Mayo Clinic. The accolade was awarded by a team of six judges from across the Department of Health and Human Services in the United States.
Venous Thromboembolism (VTE) is a medical term that relates to blood clots that form in deep veins inside the body (deep vein thrombosis), in the lungs (pulmonary embolism), or both. Women who are pregnant or who have recently had a baby have an increased chance of developing blood clots. If they develop, these blood clots can cause serious ill-health to the new mother and in rare circumstances can be life threatening.
The U.S Centre for Disease Control and Prevention stated “Out of the many outstanding submissions received, the Rotunda Hospital’s submission was chosen as one of four to be awarded Honourable Mention for the innovative and unique approach to prevention of blood clots in special populations and settings.”
Thrombocalc was developed by a multidisciplinary team in the Rotunda Hospital, and was introduced into clinical practice in late 2014. Thrombocalc is an easy to use electronic toolwhich allows rapid, accurate assessment of each woman’s risk of blood clots after delivery. The tool has been demonstrated to be highly effective in facilitating the performance and recording of this essential risk assessment. In the last quarter of 2015, the tool was used to assess the risk of blood clots in 92% of women delivering in the Rotunda Hospital.
An online version was developed in collaboration with MEG Clinical Support Tools, an Irish health technology company, and the Thrombocalc team is currently collaborating with other healthcare institutions throughout Ireland on strategies to improve risk assessment methods and expand the use of Thrombocalc in the prevention of pregnancy associated clots.
Professor Fergal Malone, Master of the Rotunda Hospital said “I would like to congratulate all those involved in the development and implementation of Thrombocalc on receiving an Honourable Mention. I am delighted that the innovation and hard work demonstrated by the team, and the midwives and nursing staff, who have incorporated this risk assessment tool as part of their standard of care, are being given prestigious international recognition by CDC.”
A dedicated website has been launched by CDC, which features profiles of the awarded initiatives, including the Rotunda Hospital and Thrombocalc. The website can be found here.